A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Endometrial cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 12 Sep 2017 Interim results (n=30; data cut off: 15 Feb, 2017) from the renal cell carcinoma cohort, presented at the 42nd European Society for Medical Oncology Congress.
- 11 Sep 2017 Results from the renal cell carcinoma cohort (n = 30) published in an Eisai Co media release.
- 10 Sep 2017 Interim results from the advanced renal cell carcinoma (RCC) cohort of the study published in an Eisai Inc media release.